Under the data of Russian Federal State Registry 2010 there are around 3 million patients in diabetes. Also data of epidemiology assessment in the frame of national project "Health" demonstrates that estimated number of patients consists of 5-7% from total population that is 4 times higher. Death rate of cardiovascular complications is 1.5 thousand people per year. Every second patient gets invalidity. So total expenditures for complications treatment tens times more than costs on medical products and control devices. OBJECTIVES: 1) Provide local costs of the disease, and 2) Assess benefits of new technology treatment versus traditional therapy. METHODS: Retrospective analysis of case studies of patients in D2T from 4 regions of Russia. Average age - 61 years, duration of D2T - 7.5 years, body mass index - more than 32 kg/m3, Hb1Ac - 8.1%. Isolation of two groups of patients: 1 - treated with adding of vildagliptin (n=264); 2 - treated by traditional OAD with sulfonylurea (n=600). Comparative analysis "Cost of Illness" of two groups, and correlation between antidiabetic medical products and risk of fatal complications. RESULTS: Average cost of antidiabetic medical treatment of group 1 versus 2 is more than 2 times expensive, 16,600 rub versus 7,000 rub per patient rep year. Exchange rate is $1 = 30 rub. But total costs for the treatment of patients group 2 versus 1 is 30% higher (26,000 rub and 18,000 rub per patient per year accordingly). The main reason - more number of vital important cardiovascular events and exacerbations of hypertension and heart disease in group 2. Part of direct medical costs for the treatment without antidiabetic products is 7% and 73% from total costs for groups 1 and 2 accordingly. CONCLUSIONS: Usage of new antidiabetic products - vildagliptin is a way to control of diabetes, development of cardiovascular complications and total budget for the disease.